三星將推低價學名藥 槓歐美廠 - 生技

※ 引述《espana (下一站 未知)》之銘言：
: 標題: Re: [新聞] 三星將推低價學名藥 槓歐美廠
: 時間: Tue Apr 24 07:51:59 2012
:
: 由今天新聞看起來 Pfizer 搞學名藥的日子越來越近了

之前就想搞過了 想藉此搶新興市場
http://ppt.cc/hLYL

結果又不明原因放棄
http://ppt.cc/fhnv

: 推 lingon:感覺上這是趨勢, 大藥廠逐漸以併購outsource為主, 生科戰國 04/24 11:42
: → lingon:亂世似乎逐漸開始... 04/24 11:43
: 推 moon0617:請問是哪一則新聞呢 有連結嗎 04/24 12:46
http://ppt.cc/ePAR

Next Step For Pfizer After Nestle Sale: Get Drugs Approved, Sell Them

Pfizer announced today that it is selling its nutritional business, a leading
maker of infant formula in Asia, Europe, and Latin America, to Nestle for
$11.85 billion or nearly 20 times the division’s EBITDA. That’s nearly $2
billion more than analysts were forecasting the business might get last year,
when I first reported on the idea that the drug giant might be spinning off
non-core divisions. The Pfizer baby formula unit is expected to generate $2.4
billion in sales this year.

That Pfizer got such a good price is obviously a win for investors. The
company will be using the money to buy back shares, according to a statement
by chief executive Ian Read – unless, he says, he can find a better way to
put it to use. But shares edged down sixteen cents to $22.40 this morning,
so, obviously, this victory was already baked in.

What’s next? For one thing, investors are likely to turn their eyes to
another sale. Pfizer has already said it will also explore options for its
animal health business, which sells veterinary drugs. Last year, I pegged the
value of this $3.9 billion (sales) division at $16 billion. There could be
more upside there.

A more important question – really, the big, meta-argument around both asset
divestitures – is whether the world’s largest drug company will be able to
go even further in taking itself apart. The big bull argument is that Pfizer
will eventually get rid of its consumer health division too, and then build
up its established products business into a generics business that can also
be sold or spun off. That would leave a smaller, faster-growing
pharmaceutical company. Some Wall Street analysts, including Jami Rubin at
Goldman Sachs, have been fans of this idea for years.

Richard Evans, of research firm Sovereign & Sector, has made the
counter-argument that even if you spin off all the really old, nearly generic
drugs, most of Pfizer’s products are still pretty old, and that the company’
s research and development spending won’t produce enough hits to make that
new, smaller company, nearly so compelling.

Lest we forget, the key to running a successful drug company is not spinning
off existing divisions but inventing new drugs, bringing them to market, and
then selling them. Key events by which Pfizer’s research efforts will be
judged are approaching.

On May 9, the company’s key rheumatoid arthritis pill, tofacitinib, will go
before a panel of experts chosen by the Food and Drug Administration. The
potential for this drug is very big, but the big question is whether it will
be able to compete directly with Abbott Laboratories’ injectible Humira –
expected to soon be the best-selling drug in the world – or whether it will
be relegated to use afterward, at least at first.

Also this summer, Eliquis, a new blood thinner for patients at high risk of
stroke Pfizer has developed with Bristol-Myers Squibb, could be approved; the
FDA is due to make a decision on June 28. Also worth watching: a study, due
to complete in August 2013 with results due in December 2014, of whether the
company’s Prevnar 13 vaccine prevents pneumonia in adults. Sales of other
new products, like cancer drug Xalkori, will also be key.

短評:

之前說併購可以增加競爭力 降低營運成本
過沒幾年 又準備拆分說要專注核心本業

CEO 和 顧問公司表示: 賺得好飽...

--
一切都是華爾街的陰謀?

--